Prevention and treatment of high-altitude illness in travelers

World Health Organization: World health statistics annual 1995. Geneva: World Health Organization; 1996. Honigman B, Theis MK, Koziol-McLain J, et al.: Acute mountain sickness in a general tourist population at moderate altitudes. Ann Intern Med 1993, 118:587–592. Hackett PH, Rennie D, Levine HD: The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 1976, 2:1149–1155. This is a landmark paper describing the epidemiology of AMS among travelers in the Mt. Everest region of Nepal. Hackett PH, Rennie D: Rales, peripheral edema, retinal hemorrhage and acute mountain sickness. Am J Med 1979, 67:214–218. Murdoch DR: Altitude illness among tourists flying to 3740 meters elevation in the Nepal Himalayas. J Travel Med 1995, 2:255–256. Maggiorini M, Bühler B, Walter M, Oelz O: Prevalence of acute mountain sickness in the Swiss Alps. BMJ 1990, 301:853–855. Gabry AL, Ledoux X, Mozziconacci M, Martin C: High-altitude pulmonary edema at moderate altitude (<2,400 m; 7870 feet). A series of 52 patients. Chest 2003, 123:49–53. Roach RC, Maes D, Sandoval D, et al.: Exercise exacerbates acute mountain sickness at simulated high altitude. J Appl Physiol 2000, 88:581–585. Milledge JS, Beeley JM, Broome J, et al.: Acute mountain sickness susceptibility, fitness and hypoxic ventilatory response. Eur Respir J 1991, 4:1000–1003. Bircher HP, Eichenberger U, Maggiorini M, et al.: Relationship of mountain sickness to physical fitness and exercise intensity during ascent. J Wilderness Med 1994, 5:302–311. Pollard AJ, Niermeyer S, Barry P, et al.: Children at high altitude: an international consensus statement by an ad hoc committee of the International Society for Mountain Medicine, March 12, 2001. High Alt Med Biol 2001, 2:389–403. This review and consensus statement summarizes current knowledge regarding the health problems of children at high altitude. Roach RC, Houston CS, Hongiman B, et al.: How well do older persons tolerate moderate altitude? West J Med 1995, 162:32–36. Kayser B: Acute mountain sickness in western tourists around the Thorong pass (5400 m) in Nepal. J Wilderness Med 1991, 2:110–117. Murdoch DR, Curry C: Acute mountain sickness in the Southern Alps of New Zealand. N Z Med J 1998, 111:168–169. Basnyat B: Neck irradiation or surgery may predispose to severe acute mountain sickness. J Travel Med 2002, 9:105. Murdoch DR: Symptoms of infection and altitude illness among hikers in the Mount Everest region of Nepal. Aviat Space Environ Med 1995, 66:148–151. Durmowicz AG, Noordeweir E, Nicholas R, Reeves JT: Inflammatory processes may predispose children to high-altitude pulmonary edema. J Pediatrics 1997, 130:838–840. Silber E, Sonnenberg P, Collier DJ, et al.: Clinical features of headache at altitude: a prospective study. Neurology 2003, 60:1167–1171. Hackett PH, Creagh CE, Grover RF, et al.: High-altitude pulmonary edema in persons without the right pulmonary artery. N Engl J Med 1980, 302:1070–1073. Naeije R, De Backer D, Vachiery JL, De Vuyst P: High-altitude pulmonary edema with primary pulmonary hypertension. Chest 1996, 110:286–289. Vock P, Brutsche MH, Nanzer A, Bärtsch P: Variable radiomorphologic data of high altitude pulmonary edema. Features from 60 patients. Chest 1991, 100:1306–1311. Basnyat B, Murdoch DR: High-altitude illness. Lancet 2003, 361:1967–1974. This is a recent review of high-altitude illness, with an emphasis on recent developments in pathogenesis, prevention, and treatment. Hackett PH: The cerebral etiology of high-altitude cerebral edema and acute mountain sickness. Wilderness Environ Med 1999, 10:97–109. Roach RC, Hackett PH: Frontiers of hypoxia research: acute mountain sickness. J Exp Biol 2001, 204:3161–3170. This is a detailed review of AMS pathogenesis and related research. Swenson ER, Maggiorini M, Mongovin S, et al.: Pathogenesis of high-altitude pulmonary edema: inflammation is not an etiologic factor. JAMA 2002, 287:2228–2235. Sartori C, Allemann Y, Duplain H, et al.: Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 2002, 346:1631–1636. Murdoch DR: How fast is too fast? Attempts to define a recommended ascent rate to prevent acute mountain sickness. News Int Soc Mt Med 1999, 9:3–6. Hackett PH, Roach RC: High-altitude illness. N Engl J Med 2001, 345:107–114. This is a general review of high-altitude illness. Vann R, Pollock N, Pieper C, et al.: Epidemiological models of acute mountain sickness (AMS). High Alt Med Biol 2003, 4:451. Basnyat B, Gertsch JH, Johnson W, et al.: Efficacy of low dose acetazolamide (125 mg bid) in the prophylaxis of acute mountain sickness. High Alt Med Biol 2003, 4:45–52. Dumont L, Mardirosoff C, Tramèr MR: Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ 2000, 321:267–272. Hackett PH, Roach RC, Wood RA, et al.: Dexamethasone for prevention and treatment of acute mountain sickness. Aviat Space Environ Med 1988, 59:950–954. Johnson TS, Rock PB, Fulco CS, et al.: Prevention of acute mountain sickness by dexamethasone. N Engl J Med 1984, 310:683–686. Ellsworth AJ, Meyer EF, Larson EB: Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. West J Med 1991, 154:289–293. Ried LD, Carter KA, Ellsworth A: Acetazolamide or dexamethasone for prevention of acute mountain sickness: a metaanalysis. J Wilderness Med 1994, 5:34–48. Bernhard WN, Schalick LM, Delaney PA, et al.: Acetazolamide plus low-dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviat Space Environ Med 1998, 69:883–886. Roncin JP, Schwartz F, D’Arbigny P: EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure. Aviat Space Environ Med 1996, 67:445–452. Leadbetter G, Maakestad K, Olson S, Hackett P: Gingko biloba reduces incidence and severity of acute mountain sickness. High Alt Med Biol 2001, 2:110. Gertsch JH, Seto TB, Mor J, Onopa J: Gingko biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. High Alt Med Biol 2002, 3:29–37. Bailey DM, Davies B: Acute mountain sickness; prophylactic benefits of antioxidant vitamin supplementation at high altitude. High Alt Med Biol 2001, 2:21–29. Bärtsch P, Maggiorini M, Ritter M, et al.: Prevention of highaltitude pulmonary edema by nifedipine. N Engl J Med 1991, 325:1284–1289. Grissom CK, Roach RC, Sarnquist FH, Hackett PH: Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Ann Intern Med 1992, 116:461–465. Levine BD, Yoshimura K, Kobayashi T, et al.: Dexamethasone in the treatment of acute mountain sickness. N Engl J Med 1989, 321:1707–1713. Ferrazzini G, Maggiorini M, Kriemler S, et al.: Successful treatment of acute mountain sickness with dexamethasone. BMJ 1987, 294:1380–1382. Davis PR, Kippax J, Shaw GM, et al.: A novel continuous positive airways pressure (CPAP) device for use at high altitude. High Alt Med Biol 2002, 3:101. Oelz O, Maggiorini M, Ritter M, et al.: Nifedipine for high altitude pulmonary oedema. Lancet 1989, 2:1241–1244. Kasic JF, Yaron M, Nicholas RA, et al.: Treatment of acute mountain sickness: hyperbaric versus oxygen therapy. Ann Emerg Med 1991, 20:1109–1112. Bärtsch P, Merki B, Hofstetter D, et al.: Treatment of acute mountain sickness by simulated descent: a randomised controlled trial. BMJ 1993, 306:1098–1101. Keller HR, Maggiorini M, Bärtsch P, Oelz O: Simulated descent v dexamethasone in treatment of acute mountain sickness: a randomised trial. BMJ 1995, 310:1232–1235.